The pursuit of a healthy life has been a trendy and serious issue for decades.
Undoubtedly, emerging antibiotics will be a lighthouse to guide all mankind towards happiness.
Dr.George has involved in biomedical research field for over a decade, specializing in the research and development of new compounds and new drugs. George has achieved some impressive milestones after graduated from the Department of Plant Pathology, National Chung Hsing University:
2018-Successfully transferred the plant protection Streptomyces Padanus PMS-702 composition and preparation and further improved it into the core extraction technology-ExtrOTM.Established Anti-Microbial Savior BioteQ Co., Ltd. (AMS BioteQ).
2021-AMS BioteQ joined the emerging stock market successfully in Dec.
CEO Calvin holds an MBA in Business Administration with a focus on Finance from California State Polytechnic University, Pomona. With expertise in venture capital, he has served as a director of the Securities Over-the-Counter Market and as a board member of the Securities and Futures Investors Protection Center in Taiwan. As the Chairman of Taiwan Venture Capital and Taishin Securities Venture Capital, he has led companies to growth and innovation in a competitive market.
Dr. Yi-Wei Chang , Vice President, holds a Ph.D. from National Taiwan University in Food Science. Specializing in drug development, quality control, and polysaccharide testing, he is certified in ISO/IEC 17025 and GLP. With expertise in food and pharmaceutical innovation, he drives quality and competitive advantage through cross-disciplinary integration.
Ms. Hsu Li-Yu, Director, graduated from National Chung Hsing University. She specializes in internal control, auditing, and IPO guidance, with expertise in accounting and shareholder services. Her leadership drives corporate efficiency, compliance, and growth.
Director Yeh is graduated from the Institute of Biomedical Engineering, National Taiwan University of Science and Technology, specializing in the development and application of drug carriers and wound dressings. Mainly executing 2019 CITD and 2020 SBIR phase I, respectively.
Hong is graduated from the Department of Biomedical Sciences and Engineering, National Central University, specializing in biomaterial and related techniques, major in the development and application of hydrogel dressings.
Dr. Chao Yung-Mei , a graduate of National Cheng Kung University, specializes in biomedical research, cell signaling, and animal physiology. She fosters collaborations between industry and academia, driving innovation in the biomedical field.
Dr. Chou Chih-Hung , a Ph.D. from National Sun Yat-sen University, specializes in organic synthesis and chemical biology. He designs bioactive molecules and explores their biological applications, driving innovation at the intersection of chemistry and biology.
Dr. Wang Hui-Ru , a graduate of National Sun Yat-sen University, specializes in quality auditing and product development. She has established and optimized the company’s QMS, ensuring international standards compliance. Her expertise drives cross-departmental collaboration, enhancing efficiency and competitiveness.
Dr. Weng ChenChia, a graduate of National Cheng Kung University, specializes in surfactant research and data analysis. He uses advanced techniques to optimize surfactant performance, enhancing product efficiency and reducing environmental impact.
Dr. Richa Pandey , a graduate of Kaohsiung Medical University, specializes in drug development, oncology, and nanomedicine. She excels in interdisciplinary research, driving innovation in cancer treatment and nanotechnology applications.
Ms. Hsiuyun Chen , Assistant Manager, specializes in marketing planning, brand public relations, and exhibition planning. Leveraging her strong design background and creative thinking, she excels in integrating brand concepts with market demands to craft unique marketing strategies and visual identities. Focused on enhancing brand image and market influence, she creates significant commercial value for enterprises.
